Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24530659 | 0.89 | TP53 (0.56) | TP53SMN1; SMN2MEN1KMT2ADRD2 | |
| SCHEMBL25477805 | 0.84 | SMN1; SMN2 (0.44) | TP53SMN1; SMN2HTR4MEN1KMT2A | |
| SCHEMBL25913732 | 0.84 | SMN1; SMN2 (0.44) | TP53SMN1; SMN2HTR4MEN1KMT2A | |
| SCHEMBL8145105 | 0.83 | NPSR1 (0.47) | TP53SMN1; SMN2HTR4CYP2C19SIGMAR1 | |
| SCHEMBL19586313 | 0.83 | HTR4 (0.46) | TP53SMN1; SMN2HTR4CYP2C19MEN1 | |
| SCHEMBL10109056 | 0.82 | MEN1 (0.48) | TP53SMN1; SMN2CYP2C19MEN1KMT2A | |
| SCHEMBL15985650 | 0.82 | HDAC2 (0.51) | TP53SMN1; SMN2CYP2C19MEN1KMT2A | |
| SCHEMBL84386 | 0.80 | CA12 (0.55) | SMN1; SMN2MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL23722070 | 0.79 | CA12 (0.53) | SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL84849 | 0.79 | ALDH1A1 (0.57) | SMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | TP53 275/4885SMN1; SMN2 4200/4885HTR4 4630/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | TP53 1344/4885SMN1; SMN2 2458/4885HTR4 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.